Metopirone (Metyrapone)

Metyrapone inhibits the enzyme 11‑beta‑hydroxylase in the adrenal cortex, blocking the final step of cortisol synthesis. This reduces cortisol output and leads to accumulation of precursor steroids, which can be measured for diagnostic purposes or used to control hypercortisolism.

The dose of Metopirone is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No standard dosing regimen is provided here.

Safety data for metyrapone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Metopirone, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other cortisol synthesis inhibitors such as ketoconazole, metyrapone offers a more selective inhibition of 11‑beta‑hydroxylase and is often preferred for diagnostic testing. However, therapeutic choices depend on the clinical scenario, side‑effect profile, and physician experience.

Metopirone should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Metopirone is taken orally, usually with water. The exact timing relative to meals and other medications is determined by the prescribing clinician to optimise absorption and therapeutic effect.

Serious risks include acute adrenal insufficiency, severe hypertension, hypokalemia, allergic reactions, and potential liver enzyme elevations. Patients should be monitored closely for these events, especially during dose adjustments.

Metopirone is contraindicated in individuals with known hypersensitivity to metyrapone, in patients with uncontrolled hypertension, and in those with severe hepatic impairment unless the benefits outweigh the risks as judged by a physician.